News >

FDA Accepts Application for Rituximab Biosimilar

Jason Harris
Published: Tuesday, Sep 12, 2017

The FDA has accepted a biologics license application (BLA) for the rituximab (Rituxan) biosimilar Rixathon (GP2013), according to Sandoz (Novartis), the company developing the treatment.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Medical Crossfire®: Personalizing Care for Multiple Myeloma Patients: Current and Future Sequencing StrategiesMay 31, 20191.5
Publication Bottom Border
Border Publication